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L angerhans cell histiocytosis (LCH) is a rare dis-ease with various clinical presentations from 
localized to disseminated features.  Patients with multi-
system LCH who are very young at onset with risk 
organ involvement,  or whose disease is refractory to 
conventional chemotherapy,  have shown poor out-
comes [1 , 2].  For these high-risk patients,  2-CdA or 
clofarabine is administered as a rescue therapy 
[3 , 4]; the alternative approach is allogenic stem cell 
transplantation (HSCT).  Several reports have suggested 
that HSCT with reduced-intensity conditioning (RIC) 
improved the outcome of LCH patients [5-9].
Hemophagocytic lymphohistiocytosis (HLH) is also 
a rare complication of LCH.  Although there have been 
only a few reports on LCH patients complicated with 
HLH,   the prognosis seems to be very poor when HLH 
occurs in refractory LCH patients [10].  
 We report the case of an infant with multisystem 
LCH complicated with HLH who was refractory to che-
motherapy,  but was successfully treated by cord blood 
transplantation (CBT) with RIC.  The benefits of CBT 
with the RIC regimen are discussed.
Case Report
A one-year-old girl exhibited a recurrent fever 
refractory to antibiotics with left cervical lymphade-
nopathy as well as a skin rash on her head lasting five 
months.  She was admitted to our hospital for further 
examination and treatment.  At admission,  she had a 
high fever with tachypnea and tachycardia.  Physical 
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We diagnosed a female infant with Langerhans cell histiocytosis (LCH) who was refractory to conventional che-
motherapy.  She showed refractory inflammation that was complicated with hemophagocytic lymphohistiocy-
tosis (HLH) during LCH chemotherapy; therefore,  we changed the protocol to HLH2004 (dexamethasone,  
cyclosporine A and VP16).  However,  there were no signs of hematological recovery.  We therefore performed 
cord blood transplantation with reduced-intensity conditioning,  and she achieved complete remission for over 
2 years.  As salvage therapy for refractory LCH,  hematopoietic stem cell transplantation may be a good thera-
peutic choice,  especially when LCH is complicated with HLH.
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examination revealed bilateral massive cervical lymph-
adenopathy,  hepatomegaly,  skin rash of bilateral 
postauricular lesions and inguens.  Her blood test 
showed severe anemia,  coagulopathy,  elevation of 
C-reactive protein,  and hypoalbuminemia.  Soluble 
IL-2 receptor and liver fibrotic marker levels were ele-
vated (Table 1).  Computed tomography showed mas-
sive cervical lymphadenopathy,  hepatomegaly,  and 
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Table 1　 Blood examination on admission
WBC 5,410 /µl TP 4.4 g/dl
Neu 41 % Alb 2.1 g/dl
Hb 5.9 g/dl T.Bil 0.59 mg/dl
Plt 22.5 ×104/µl D.Bil 0.09 mg/dl
AST 9 U/l
Fibg 649 mg/dl ALT 2 U/l
PT-INR 1.27 ALP 197 U/l
AT3 62 % γGTP 9 U/l
FDP 10.1 µg/ml CHE 45 U/l
LD 168 U/l
slL2-R 5,410 U/ml
Type 4 collagen 4.2 ng/dl UN 6.4 mg/dl
Hyaluronic acid 94.8 ng/dl CRTN 0.19 mg/dl
AFP 2.5 ng/dl
T.Cho 127 mg/dl
TG 131 mg/dl
ferritin 169.1 ng/dl
CRP 10.7 mg/dl
Blood test of the patient on admission.  Abnormal data represented by thick letters.  It showed severe anemia,  coagulopathy,  elevation of 
CRP,  and hypoalbuminemia.  Soluble lL-2 receptor and liver ﬁbrotic marker levels were elevated.
Fig. 1　 Images of computed tomogra-
phy on admission.  A,  3D reconstruction 
showed multiple bone lesions on the skull;  
B,  Lymphadenopathy and hepatomegaly 
were observed; C,  Lung lesions were 
observed.  We could not tell whether they 
were caused by an infection or LCH; D,  
She also had bone lesions on her verte-
brae.
infiltration of the lower lung area (Fig. 1).  Multiple 
punched-out bone lesions were observed on the 
temporal bone,  orbit,  vertebra,  and pelvis.  Bone mar-
row aspiration resulted in a dry tap.  Abnormal cells 
with rich cytoplasm were observed on the smear sam-
ple,  but there was no sign of hemophagocytosis.  
Patho-histologic examination of a cervical lymph node 
revealed a proliferation of polymorphic and dysplastic 
abnormal cells stained positively with S100 and CD1a,  
which had replaced the normal lymphatic tissue.  From 
these results,  the patient was diagnosed with LCH 
(Fig. 2A).  
  We started administration of prednisolone (PSL) 
and chemotherapy following the Japan LCH Study 
Group (JLSG)-02 induction A protocol [1].  She 
returned to an afebrile state,  and the lymphadenopathy 
was gradually reduced; however,  the skin rash and 
hepatomegaly were still present.  After 3 weeks,  she 
developed recurrent fever with pancytopenia,  elevation 
of serum ferritin,  biliary enzyme,  and progressive 
coagulopathy (Table 2).  Bone marrow aspiration 
revealed massive hemophagocytosis and hypocellular 
marrow (Fig. 2B).  Epstein-Barr virus and cytomegalo-
virus were negative on RT-PCR.  We diagnosed her with 
secondary HLH following LCH,  and changed the pro-
tocol to HLH2004 (dexamethasone,  cyclosporine A and 
VP16) [11].  After 1 month,  her peripheral ferritin 
level was around 800 ng/ml,  and neutropenia contin-
ued.  She achieved an afebrile state only with the use of 
acetaminophen for pain control.  Hemophagocytosis 
was observed in her bone marrow,  and there was no 
sign of normal hematopoiesis; therefore,  we consid-
ered performing HSCT (Fig. 3).  She had no HLA-
matched related donor,  and received 8 / 8 HLA-
matched cord blood transplantation (CBT) with RIC.  
We chose fludarabine (Flu; 180 mg/sqm) and mel-
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A.  Patho-histologic examination of cervical lymph node
B.  Bone marrow aspiration; May-Grunwald Giemsa staining （onset of HLH）
HE CD1a S-100
Fig. 2　 A.  Patho-histologic examination of the cervical lymph node on admission.  The normal lymphatic tissue was replaced with a 
proliferation of polymorphic and dysplastic abnormal cells stained positively with S100 and CD1a.  B.  Bone marrow aspiration at the onset 
of hemophagocytic lymphohistiocytosis.  May-Grunwald Giemsa staining was performed.
phalan (L-PAM; 140 mg/sqm) as the conditioning 
regimen.  We also intensified the conditioning with 
antithymocyte globulin (ATG; 2.5 mg/kg) and low-
dose cyclophosphamide (CY; 100 mg/sqm) as immu-
nosuppressants.  Successful engraftment was confirmed 
by bone marrow examination on day 33,  and short 
tandem repeat revealed over 95% donor type.  After 
neutrophil engraftment,  we gradually reduced PSL dos-
age,  and there was no sign of refractory fever or 
hemophagocytosis.  Stage 1 skin rash was the only 
symptom of graft-versus host disease.  Neither virus 
reactivation nor fungal infection was observed.  She was 
discharged 3 months after CBT,  and no recurrence of 
LCH or HLH has been observed during a follow-up of 
more than 2 years.
Discussion
LCH is a rare clonal disorder characterized by the 
proliferation and accumulation of clonal CD1a-positive 
immature dendritic cells,  accompanied by the infiltra-
tion of various inflammatory cells [1 , 2].  The clinical 
presentation of LCH is highly variable,  ranging from 
benign localized to disseminated aggressive disease,  
which may be fatal.  Patients under 2 years of age at 
onset who have involvement of one ore more ‘risk 
organs’ including the hematopoietic system,  liver,  
spleen,  and lung,  or are refractory to conventional che-
motherapy have a poor outcome with a survival rate of 
less than 30% at 2 years [5].
Macrophage activation and secondary HLH are 
rarely reported in association with LCH.  Blaise et al.  
reviewed 30 LCH cases that had pathological signs of 
macrophage activation [10].  They concluded that mul-
tisystem LCH and young age are factors for macrophage 
activation.  Of the 7 patients who had fully developed 
HLH,  4 died.  Therefore,  the complication of HLH 
might increase the mortality rate of high-risk LCH [10].
In our patient,  high risk organs such as the liver,  
bone marrow,  and lung were involved.  She also had 
suffered inflammation,  her disease was refractory to 
conventional chemotherapy,  and finally she developed 
HLH during the clinical course.  After one month of 
HLH 2004 therapy,  she could not achieve remission of 
LCH or HLH.  She had hypertension and hyperglyce-
mia as complications of the diseases and therapies,  sug-
gesting the progression of endothelial disorder.  We 
expected that her prognosis would be very poor; there-
fore,  we planned salvage HSCT as soon as possible.  
Several studies have described the application of 
HSCT for refractory LCH.  In those reports,  myeloab-
lative conditioning appears to be related with high 
treatment-related-mortality rate [5 , 9].  However,  other 
reports have suggested that HSCT with RIC could be a 
promising salvage therapy for refractory LCH [5-9].  
Kudo et al.  reported that HSCT with a Flu + L-PAM 
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Table 2　 blood examination at the onset of HLH
WBC 960 /µl TP 3.7 g/dl
Neu 4 % Alb 2.0 g/dl
Hb 6.9 g/dl T.Bil 1.31 mg/dl
Plt 13.3 ×104/µl D.Bil 0.49 mg/dl
AST 5 U/l
Fibg 919 mg/dl ALT 2 U/l
PT-INR 1.25 ALP U/l
AT3 81 % γGTP 9 U/l
FDP 5.3 µg/ml CHE 18 U/l
LD 80 U/l
slL2-R 2,492 U/ml
UN 7.9 mg/dl
EBV-PCR 0 Copies/µgDNA CRTN 0.14 mg/dl
CMV-PCR 0 Copies/µgDNA
T.Cho mg/dl
TG 188 mg/dl
ferritin 897.5 ng/dl
CRP 13.2 mg/dl
Blood test of the patient on admission.  Abnormal data represented by thick letters.  It showed rapidly progressed anemia and neutropenia,  
elevation of CRP,  ferritin,  and soluble IL-2 receptor It also showed hypoalbuminemia.  No evidence of reactivation of EBV nor CMV.
regimen was safely and successfully performed in 15 
refractory LCH patients [7].  We chose cord blood stem 
cell transplantation; therefore,  we intensified the con-
ditioning with ATG and low-dose CY as an immuno-
suppressant to avoid engraftment failure.   Fortunately,  
our patient had no severe complications with HSCT,  
showed successful engraftment,  and has been in com-
plete remission for over 2 years.
In conclusion,  immune system recovery by HSCT 
with RIC may be a treatment option for refractory LCH 
with HLH.  HSCT with RIC as a possible salvage ther-
apy for refractory LCH should be considered.  
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